Genomic Maps of Endometrial Tissues of Patients With Endometriosis and Healthy Controls
Comparison of Genomic Maps of Endometrial Tissues of Patients With Endometriosis and Healthy Controls Via Nanochannel Technique and Proteomic-genomic Analyzes.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Bahar Yuksel, md
- Phone Number: 05424732003
- Email: baharyl86@gmail.com
Study Contact Backup
- Name: ercan bastu, md
- Email: ercanbastu@gmail.com
Study Locations
-
-
-
Istanbul, Turkey, 34104
- Recruiting
- Bahar Yuksel
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
patients who are :
- surgically diagnosed with endometriosis disease
- have no diagnosıs for malignancy
- gave informed consent for application to the study enrolle as patient group
females
- between 18-45 years old
- without any health conditions
- applied to the clinic for routine checkups are going to be taken as the control group
Description
Inclusion Criteria:
surgically diagnosed with endometriosis disease
- no diagnosıs for malignancy
- gave informed consent for application to the study enrolle as patient group females
- between 18-45 years old
- without any health conditions
- applied to the clinic for routine checkups for control group
Exclusion Criteria:
- being diagnosed with any kind of malignancy having trouble with endometrial cavity sampling
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
control
does not have endometriosis or related diseases and not under any drug therapy does not have any benign or malign disease
|
endometrial sampling
|
|
patient
has laparoscopically proven endometriosis
|
endometrial sampling
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
diagnostic testing
Time Frame: 2 years
|
finding a genetic difference which specifically preserved in endometriosis patients but not in healthy controls.
To analyse the different region on chromosomes and name the pathophysiology underlying it
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Bahar Yuksel, MD
Publications and helpful links
General Publications
- Cao H, Hastie AR, Cao D, Lam ET, Sun Y, Huang H, Liu X, Lin L, Andrews W, Chan S, Huang S, Tong X, Requa M, Anantharaman T, Krogh A, Yang H, Cao H, Xu X. Rapid detection of structural variation in a human genome using nanochannel-based genome mapping technology. Gigascience. 2014 Dec 30;3(1):34. doi: 10.1186/2047-217X-3-34. eCollection 2014.
- Kobayashi H, Imanaka S, Nakamura H, Tsuji A. Understanding the role of epigenomic, genomic and genetic alterations in the development of endometriosis (review). Mol Med Rep. 2014 May;9(5):1483-505. doi: 10.3892/mmr.2014.2057. Epub 2014 Mar 14.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- AcibademU endo
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.